Ronald W Penczek sold $184k of ELV
CAO & Controller at Elevance Health, Inc.. 443 shares at an average of $415.13, traded Mar 10, 2025, filed Mar 11, 2025.
Score components
- +15RoleOfficer
- +12Trade size$184k at market
- +5Share of holdings soldSold 19% of holdings
- +8Cluster2 insiders selling within 14 days
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001156039-25-000038, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Mar 10, 2025 | SOpen-market sale Common Stock | -443 | $415.13 | $184k | 1,847 | Mar 11, 2025 |
Related signals
Other insiders at Elevance Health, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 48Moderate | ELVbuy Elevance Health, Inc. | Susan D. DeVore director | $375k 1,200 shares | +52% | |
| 71Notable | ELVbuy Elevance Health, Inc. | Gail Boudreaux President and CEO | $2.4M 8,500 shares | +6% | |
| 52Moderate | ELVsell Elevance Health, Inc. | Mark Kaye EVP & CFO | $1.9M 4,588 shares | -19% | |
| 58Moderate | Elevance Health, Inc. | Charles Morgan Kendrick JR EVP & President, Commercial | $1.4M 3,504 shares | -26% | |
| 50Moderate | ELVsell Elevance Health, Inc. | Charles Morgan Kendrick JR EVP & President, Commercial | $3.2M 7,417 shares | -47% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.